During the past decade, treatment strategies for patients with advanced prostate cancer
involving stage IV (T4N0M0, N1M0 or M1) hormone‐sensitive prostate cancer and recurrent …

Purpose: The summary presented herein represents Part II of the two-part series dedicated
to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and …

Background There is an urgent need to identify biomarkers to guide personalized therapy in
castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen …

Purpose Prognostic models for overall survival (OS) for patients with metastatic castration-
resistant prostate cancer (mCRPC) are dated and do not reflect significant advances in …

The adrenal gland is a source of sex steroid precursors, and its activity is particularly
relevant during fetal development and adrenarche. Following puberty, the synthesis of …

Purpose Trials in castration-resistant prostate cancer (CRPC) need new clinical end points
that are valid surrogates for survival. We evaluated circulating tumor cell (CTC) enumeration …

ABSTRACT The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC)
Expert Panel identified and reviewed the available evidence for the ten most important areas …

Various preclinical models have been developed to clarify the pathophysiology of prostate
cancer (PCa). Traditional PCa cell lines from clinical metastatic lesions, as exemplified by …

The treatment landscape of metastatic prostate cancer has evolved significantly over the
past two decades. Several landmark phase 3 trials led to new drug approvals and rapid …

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions
regarding the workup of patients with prostate cancer, risk stratification and management of …